ACADIA Pharmaceuticals Inc. ( (ACAD) ) has released its Q1 earnings. Here is a breakdown of the information ACADIA Pharmaceuticals Inc. presented to its investors.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Acadia Pharmaceuticals Inc., a leader in neuroscience breakthroughs, focuses on developing and commercializing treatments for neuropsychiatric and neuro-rare diseases, including Parkinson’s disease psychosis and Rett syndrome. In its first quarter of 2025, Acadia Pharmaceuticals reported a robust financial performance with total revenues reaching $244.3 million, marking a 19% increase compared to the previous year. The company saw significant growth in its key products, NUPLAZID and DAYBUE, with net sales rising by 23% and 11% respectively year-over-year. The company also highlighted its strategic expansion efforts, including a 30% increase in the DAYBUE field force and the first shipment of DAYBUE to a European patient under a managed access program. Acadia’s research and development expenses rose to $78.3 million, reflecting increased investment in clinical-stage programs, while selling, general, and administrative expenses also saw an uptick due to consumer activation initiatives. Looking ahead, Acadia maintains its optimistic revenue guidance for 2025, with expectations for continued growth in its product sales and advancements in its clinical trials, particularly the COMPASS PWS Phase 3 study, which is anticipated to yield results by early Q4 2025.